Research programme: ribonuclease conjugates and fusion proteins - Tamir Biotechnology

Drug Profile

Research programme: ribonuclease conjugates and fusion proteins - Tamir Biotechnology

Alternative Names: AC RN-321; AC-CJ-002; AC-RD-3002; AC-RD-3003; Ranpirnase-antibody conjugates; RN-321; rRNP-EGF

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Alfacell Corporation; National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer Johns Hopkins University; University of Duisburg-Essen
  • Class Immunoconjugates; Monoclonal antibodies; Ribonucleases
  • Mechanism of Action Mitosis inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma
  • Discontinued Autoimmune disorders; Glioma; Inflammation; Neuroblastoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Germany (Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top